Original research

High prevalence of multiple serotypes of pneumococci in patients with pneumonia and their associated risk factors

Bhim Gopal Dhoubhadel,1,2 Motoi Suzuki,3 Tomoko Ishifuji,4 Makito Yaegashi,5 Norichika Asoh,6 Masayuki Ishida,7 Sugihiro Hamaguchi,8 Masahiro Aoshima,9 Michio Yasunami,10 Koya Ariyoshi,2,4 Konosuke Morimoto,1 Adult Pneumonia Study Group-Japan (APSG-J)

ABSTRACT

Background Multiple serotypes of pneumococci have epidemiological and clinical implications, such as the emergence of non-vaccine serotypes and the acquisition of antimicrobial resistance. Prevalence of multiple serotypes of pneumococci in adults and their risk factors are not known.

Methods We enrolled adult patients from age ≥15 years with radiologically confirmed pneumonia in four hospitals across Japan. Pneumococcal pneumonia was defined with a pneumococcal bacterial density of ≥10^5/mL in sputum by multiplex quantitative PCR, and serotypes were determined. Pneumonias with a single serotype were categorised as single-serotype pneumococcal pneumonia and with two or more serotypes as multiple-serotype pneumococcal pneumonia. Multivariable logistic regression was used to assess the risk factors.

Results 3470 patients (median age 77 years, IQR 65–85) were enrolled. Pneumococcal pneumonia was identified in 476 (13.8%, n=2605) patients. Multiple serotypes were detected in 42% of them. Risk of having multiple serotypes was low among patients who had received 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccines (adjusted OR 0.51 (95% CI 0.27 to 0.94)). Proportion of non-PCV7 PPSV23 serotypes in overall distribution of multiple serotypes was 67.4% (n=324/481) compared with 46.4% (n=128/276) in that of single serotypes (p=0.001). Serotypes 5, 9N/9L, 10A, 12/22/46, 17F and 35F were associated with multiple-serotype pneumonia, and serotypes 6A/6B, 23F, 11 and 6C/6D were associated with single-serotype pneumonia. Proportion of more invasive serotypes (serotypes 1, 5, 7F, 8) was significantly higher in multiple-serotype pneumonia (p=0.001).

Conclusions Multiple serotypes of pneumococci are common in sputum of adult patients with pneumonia. The risk of multiple-serotype pneumococcal pneumonia is lower than that of single-serotype pneumococcal pneumonia among PPSV23-vaccinated patients.

Trial registration number UMIN000006909.

INTRODUCTION

Streptococcus pneumoniae is a common cause of community-acquired pneumonia (CAP) worldwide. After introduction of pneumococcal conjugate vaccines, the diseases caused by vaccine serotypes have reduced remarkably; however, the incidence of pneumonia caused by non-vaccine serotypes has continually increased, particularly in adults.1–5 Pneumococcal pneumonia can be divided into invasive (bacteraemic) and non-invasive (nabacteremic), and majorities are non-invasive.6 7 Because of the nature of non-invasive infection, difficulty to get good quality sputum and a prior use of antibiotics, conventional culture methods are not efficient to diagnose non-invasive pneumococcal pneumonia.8 9 Real-time PCR has become an established method to diagnose pneumococcal pneumonia in sputum because of its increased sensitivity and decreased turnaround time.8 10

Key messages

What is already known on the topic?

⇒ More than one serotype of pneumococci can simultaneously colonise the nasopharynx in adults and can cause invasive diseases.

⇒ Prevalence of multiple serotypes of pneumococci among adult patients with pneumococcal pneumonia and their associated risk factors are unknown.

What this study adds?

⇒ For the first time, this study reports a high prevalence of multiple serotypes of pneumococci among patients with pneumococcal pneumonia, and patients who had 23-valent pneumococcal polysaccharide vaccine had a lower risk of having multiple-serotype pneumococcal pneumonia as compared with single-serotype pneumococcal pneumonia.

How this study might affect research, practice or policy

⇒ This study highlights the need for further research in the protection offered by the 23-valent pneumococcal polysaccharide vaccine on prevention of multiple-serotype pneumococcal pneumonia, which may affect the future pneumococcal vaccine policy.
Pneumococcus has at least 98 serotypes that have potential to cause invasive (eg, meningitis, bacteraemia) and non-invasive (eg, pneumonia, sinusitis, otitis media) diseases. Although only single-serotype infection is generally reported, which is because of limitation of the conventional culture and identification methods, simultaneous infections with two serotypes have been reported. Serotype 9V and serotype 7 were isolated in the cerebrospinal fluid (CSF) in a man aged 60 years with meningitis. Similarly, in a 10-month-old infant, serotype 23B was isolated from the CSF, and serotype 23F was isolated from the blood. Pneumococci are highly recombinogenic transformable bacteria; when two or more than two serotypes are present, they can exchange genetic material that has implications for adaptation with host, drug resistance, biofilm formation and emergence of non-vaccine serotypes, which may lead to treatment failure and reduced effectiveness of vaccination. Besides these case reports, to our knowledge, only one epidemiological study about multiple-serotype infections that caused invasive pneumococcal diseases has been published. There is no published study that describes the epidemiological and clinical characteristics of multiple-serotype infections in adults with non-invasive pneumonia. We did a multicentre cross-sectional study of adult patients with pneumonia and applied an advanced PCR system that can identify more than one serotype of pneumococci simultaneously. Here, we describe the epidemiological and clinical characteristics of adult patients with multiple-serotype pneumococcal pneumonia by comparing with those with single-serotype pneumococcal pneumonia.

METHODS

Study design

The Adult Pneumonia Study Group-Japan conducted this study as a part of the multicentre prospective cross-sectional study of adult pneumonia in four main islands in Japan. The study sites were: Ebetsu City Hospital in Hokkaido; Kameda Medical Centre in Chiba; Chikamori Hospital in Kochi and Juuenkai Hospital in Nagasaki. This study was a part of the surveillance study that was carried out from 28 September 2011 to 23 August 2014 and was registered in the University hospital Medical Information Clinical Trial Registry.

Study population

Patients who fulfilled these three criteria in the emergency and outpatient departments were enrolled: (1) age ≥15 years, (2) symptoms suggestive of pneumonia and (3) findings suggestive of pneumonia in chest X-ray or CT scan. Pneumonia cases were classified into CAP and healthcare-associated pneumonia (HCAP) following the American Thoracic Society/the Infectious Diseases Society of America guideline. Patients who developed pneumonia after 48 hours of admission in another inpatient facility were excluded. Pneumococcal pneumonia was defined by positive lytA real-time PCR with a pneumococcal bacterial density ≥10^4 copies/mL in sputum in patients with radiologically confirmed pneumonia.

Data collection

Using a standardised data collection form, we collected demographic and clinical data from the patients and medical charts. Good quality sputum and blood specimens were collected at the time of admission. If the patients could not cough up sputum, it was induced by inhalation of hypertonic saline soon after admission, and the sputum was collected before giving antibiotics.

Chest X-rays were taken within 24 hours of admission, and CT scans were done at the treating physicians’ discretion.

RESULTS

Characteristics of the study population

Overall, 3600 adult patients with pneumonia were approached. The total number of patients enrolled was 3470 (figure 1), the median age was 77 years (IQR 65–85), 75.5% were ≥65 years old and 59.5% were male. Some 30.4% of patients had PPSV23 vaccine in last 5 years (table 1). Distribution of patients in different age groups is shown in figure 2. Sputum was available for PCR in 2605 patients. Characteristics of patients with sputum samples available and those with ‘not available for PCR’ are shown in online supplemental file 1. Among the 2605 patients, pneumococcal pneumonia was identified in 476 (18.3%) patients.

Clinical characteristics of patients with pneumococcal pneumonia

The median age was 72 years (IQR 63–82.5), 70.4% of them were ≥65 years of age and 62.4% were male. Clinical features, such as fever, hypoxaemia, leukocytosis, raised CRP, lobar
consolidation in chest X-ray and CAP were more prevalent in patients with pneumococcal pneumonia than non-pneumococcal pneumonia. Patients with pneumococcal pneumonia tended to be current smokers, and respiratory syncytial virus and rhinovirus co-infections were more prevalent in them than patients with non-pneumococcal pneumonia (table 2).

Clinical characteristics of patients with multiple-serotype pneumococcal pneumonia

Multiple serotypes were detected in 42% (n=200/476) of the patients with pneumococcal pneumonia. Demographical and clinical characteristics of patients with multiple serotypes and single serotypes are shown in table 2. The proportion of patients who received PPSV23 vaccines was lower in the multisertype group than that in the single-serotype group (19.6% vs 33.0%, p=0.007). Among patients aged ≥65 years, the proportions of PPSV23 vaccinated were 24.7% in multiple-serotype pneumonia and 38.6% in single-serotype pneumonia (p=0.029). The history of vaccination is unknown in 32.5% in multiple-serotype and 24.4% in single-serotype pneumonias (p=0.106) in the ≥65 years age group.

The risk of multiple-serotype pneumonia was lower among the PPSV23-vaccinated than PPSV23-non-vaccinated patients (aOR 0.51 (95% CI 0.27 to 0.94)) (table 3). Characteristics of PPSV23-vaccinated and PPSV23-non-vaccinated patients were compared (online supplemental file 2), and characteristics of patients with known vaccination history and unknown were also compared (online supplemental file 3), and the characteristics with significant differences were adjusted for the multivariable analyses. The association of PPSV23 with the risk of multiple-serotype pneumonia was further examined in subgroups. We found the effect size of the risk of multiple-serotype pneumonia was much less among women (aOR 0.23 (95% CI 0.07 to 0.8)) than men (aOR 0.62 (95% CI 0.3 to 1.29)); the test for interaction was not significant due to a small sample size. Similar observations were made among patients with CAP (aOR 0.40 (95% CI 0.20 to 0.82)) and lobar pneumonia (aOR 0.37 (95% CI 0.17 to 0.79)) (table 4).

Serotype distribution in single-serotype and multiple-serotype pneumococcal pneumonias

The serotype distribution is shown in figure 3. In total, 28 different serotypes/serogroups were identified. Serotype 3, 6A/6B, 10A, 11, 19F, 6C/6D and 35B were common in single-serotype pneumonia. Serotype 3, 10A, 19A, 15B/15C, 6A/6B

---

Table 1  Demographic and clinical characteristics of adult patients with pneumonia enrolled in the study

| Characteristics                        | Overall (n=3470) |
|----------------------------------------|-----------------|
| Age, median (IQR), years               | 77 (65–85)      |
| Age group, ≥65 years                   | 2621 (75.5)     |
| Male sex, n (%)                        | 2066 (59.5)     |
| Study sites, n (%)                     |                 |
| Ebetsu City Hospital                   | 424 (12.2)      |
| Kameda Medical Centre                  | 2055 (59.2)     |
| Chikamori Hospital                     | 608 (17.5)      |
| Jyuzenkai Hospital                     | 383 (11.1)      |
| Fever (>38.0°C), n=3369 (%)            | 1009 (30.0)     |
| Tachypnoea (respiratory rate ≥20/m), n=2727 (%) | 1860 (68.2)      |
| Hypoxaemia (SpO2 <90%), n=3340 (%)     | 390 (11.7)      |
| Leukocytosis (>11 000 WBC/mm³), n=3390 (%) | 1289 (38.0)     |
| C-reactive protein (>10 mg/dl), n=3368 (%) | 1096 (32.5)     |
| Chest X-ray (lobar consolidation), n (%) | 2346 (67.6)     |
| Current smoker, n=1520 (%)             | 272 (17.9)      |
| Underlying disorders, n (%)            | 2100 (60.5)     |
| Antibiotics prior to hospital visit, n=3427 (%) | 601 (17.5)      |
| Hospitalisation, n (%)                 | 2526 (72.8)     |
| Community-acquired pneumonia, n (%)    | 2273 (65.5)     |
| Received PPSV23 in last 5 years, n=2033* (%) | 617 (30.4)      |
| CURB-65 score ≥3, n=3359 (%)           | 1050 (31.3)     |
| Confusion, n=3454 (%)                  | 578 (16.7)      |
| Blood urea nitrogen >20 mg/dl, n=3370 (%) | 1382 (41.0)     |
| Respiratory rate ≥30/min, n (%)        | 1384 (39.9)     |
| Blood pressure <9060 mm Hg, n (%)      | 828 (23.9)      |
| Hospital stay, median (IQR), day, n=2535 | 15 (9–26)       |
| Outcome                                |                 |
| Improved, n (%)                        | 3075 (88.6)     |
| Transferred to another hospital, n (%)  | 87 (2.5)        |
| Others, n (%)                          | 52 (1.5)        |
| Death, n (%)                           | 256 (7.4)       |
| CURB-65 includes scores for confusion, blood urea nitrogen >20 mg/dl, respiratory rate ≥30/min, blood pressure <9060 mm Hg and age ≥65 years. |

*Known vaccine status and received the PPSV23 from >2 weeks to <5 years’ time.

---

Figure 1  Patient enrolment and identification of pneumococcal pneumonia. Flow chart shows the number of adult patients (≥15 years) from the enrolment to the identification of patients with single-serotype and multiple-serotype pneumococcal pneumonias.
Respiratory infection

and 35B were common first dominant serotypes in multiple-serotype pneumonia; serotype 10A, 5, 9N/9L, 4 and 17F were common second dominant serotypes and serotype 10A, 17F, 4, 12/44/46 and 18 were common third dominant serotypes. When overall serotype distributions were compared between these two groups of pneumonias, serotype 6A/6B, 23F, 11 and 6C/6D were associated with single-serotype pneumonia, whereas serotype 5, 9N/9L, 10A, 12/22/46, 17F and 35F were associated with multiple-serotype pneumonia (table 5). The proportions of PCV13 serotypes in single-serotype and multiple-serotype pneumonias were 46% (127/276) and 44.1% (212/481), respectively (p=0.605), whereas, non-PCV7 PPSV23 serotypes were 46.4% (128/276) in single-serotype pneumonia and 67.4% (324/481) in multiple-serotype pneumonia (p=0.001); similarly, non-PCV13 PPSV23 serotypes were 25.4% (70/276) in single-serotype pneumonia and 43% (207/481) in multiple-serotype pneumonia (p=0.001). The proportions of PPSV23 serotypes in single-serotype pneumonia and multiple-serotype pneumonia were 71.4% (197/276) and 87.1% (419/481), respectively (p=0.001). Similarly, the proportions of more invasive serotypes (serotype 1, 5, 7F and 8) were 0.72% (2/276) in single-serotype pneumonia and 7.7% (37/481) in multiple-serotype pneumonia (p=0.001).

Figure 2  Distribution of pneumonia in adults by age in Japan. Bar diagram shows the distribution of radiologically confirmed adult patients with pneumonia (black bar), single-serotype pneumococcal pneumonia (blue bar) and multiple-serotype pneumococcal pneumonia (green bar) by age group.

Table 2  Comparison of characteristics of patients with pneumococcal pneumonia versus non-pneumococcal pneumonia, and single-serotype pneumococcal pneumonia versus multiple-serotype pneumococcal pneumonia

| Characteristics                        | Pneumococcal pneumonia n=476 (%) | Non-pneumococcal pneumonia n=2129 (%) | P value | Single-serotype pneumococcal pneumonia (n=276) | Multiple-serotype pneumococcal pneumonia (n=200) | P value |
|----------------------------------------|----------------------------------|----------------------------------------|---------|-----------------------------------------------|-------------------------------------------------|---------|
| Age, median (IQR), years               | 72 (63–82.5)                     | 79 (68–86)                             | 0.001   | 73 (65–83)                                     | 71 (60.5–81)                                    | 0.022   |
| Age group, ≥65 years, n (%)            | 335 (70.4)                       | 1694 (79.6)                            | 0.001   | 209 (75.7)                                     | 126 (63.0)                                      | 0.003   |
| Male sex, n (%)                        | 297 (62.4)                       | 1284 (37.6)                            | 0.001   | 175 (63.4)                                     | 122 (61.0)                                      | 0.593   |
| Fever (≥38.0°C), n=2560 (%)            | 183 (38.9)                       | 597 (28.6)                             | 0.001   | 102 (37.4)                                     | 81 (41.1)                                       | 0.410   |
| Hypoxaemia (SpO2 <90%), n=2531 (%)     | 74 (16.3)                        | 249 (12.0)                             | 0.012   | 42 (16.0)                                      | 32 (16.8)                                       | 0.837   |
| Leukocytosis (>11,000 WBC/mm3), n=2565 (%) | 205 (43.8)                      | 788 (37.6)                             | 0.012   | 123 (45.2)                                     | 82 (41.8)                                       | 0.467   |
| C-reactive protein (>10 mg/dL), n=2551 (%) | 198 (42.5)                      | 671 (31.2)                             | 0.001   | 111 (41.0)                                     | 87 (44.6)                                       | 0.431   |
| Chest X-ray (lobar consolidation), n (%) | 347 (72.9)                      | 1396 (65.6)                            | 0.002   | 197 (71.4)                                     | 150 (75.0)                                      | 0.380   |
| Received PPSV23 in last 5 years, n=1820 (%) | 95 (27.8)                       | 471 (31.9)                             | 0.141   | 69 (33.0)                                      | 26 (19.6)                                       | 0.007   |
| Current smoker, n=1386 (%)             | 70 (25.6)                        | 172 (15.5)                             | 0.001   | 42 (26.4)                                      | 28 (24.4)                                       | 0.699   |
| Underlying disorders, n (%)            | 288 (60.5)                       | 1320 (62.0)                            | 0.544   | 171 (62.0)                                     | 117 (58.5)                                      | 0.446   |
| Community-acquired pneumonia, n (%)    | 374 (78.6)                       | 1308 (61.4)                            | 0.001   | 204 (73.9)                                     | 170 (85.0)                                      | 0.004   |
| Influenza A co-infection, n=2602 (%)   | 20 (4.2)                         | 81 (3.8)                               | 0.689   | 12 (4.4)                                       | 8 (4.0)                                         | 0.852   |
| RSV co-infection, n=2602 (%)           | 27 (5.7)                         | 73 (3.4)                               | 0.022   | 12 (4.4)                                       | 15 (7.5)                                        | 0.142   |
| Rhinovirus co-infection, n=2602 (%)    | 65 (13.7)                        | 187 (8.8)                              | 0.001   | 36 (13.0)                                      | 29 (14.5)                                       | 0.648   |
| CURB-65 score ≥3, n=2551 (%)           | 136 (29.2)                       | 670 (32.1)                             | 0.216   | 85 (31.5)                                      | 51 (26.0)                                       | 0.200   |
| Median pneumococcal bacterial load density, (log10/mL) | 7.48 | 7.50 | 7.45 | 0.920 |

CURB-65 includes scores for confusion, blood urea nitrogen >20 mg/dL, respiratory rate ≥30/min, blood pressure <90/60 mm Hg and age ≥65 years.

PPSV23, 23-valent pneumococcal polysaccharide vaccine; RSV, respiratory syncytial virus; SpO2, saturation of peripheral oxygen; WBC, white blood cells.

Dhoubhadel BG, et al. Thorax 2022;77:1121–1130. doi:10.1136/thoraxjnl-2021-217979
Correlations of PCR results with urinary antigen test and blood culture

Among 1990 patients whose urine antigen were tested, 290 were positive (14.6%) for pneumococci. Out of these 1990 patients, the PCR result was available for 1662 patients. Both the PCR and the urinary antigen test were positive in 169, and both tests were negative in 1249; the proportion of concordant results was (19+1304)/1591, that is, 83.2%. Combinations of positive results of various tests are shown in a Venn diagram (online supplemental file 5). Among the 19 patients with matched PCR and blood culture results, serotyping results of blood isolates were available for 14 patients; 13 of them were matched. One unmatched sample was 6B in blood isolate and 6C/6D in PCR. Out of the corresponding 14 sputum samples, 6 had multiple serotypes and all the dominant serotypes matched with serotypes identified in blood culture isolates. We did not observe any highly invasive serotypes among these matched serotypes.

Pneumococcal bacterial density

Median pneumococcal load density in the multiple-serotype pneumococcal pneumonia was 7.48 log10/mL (IQR 6.07–8.29 log10/mL). The serotype-specific median bacterial density of the most dominant serotypes in multiple-serotype pneumococcal pneumonia was similar to that of single-serotype pneumonia (7.89 log10/mL vs 7.79 log10/mL); however, the bacterial density of other serotypes in multiple-serotype pneumonia was about 2 log10/mL lower than the dominant serotype (p=0.001) (figure 4). Pneumococcal load density was found to be positively correlated with CRP and CURB-65 scores, and negatively with SpO2 in single-serotype pneumonia, whereas in multiple-serotype pneumonia, the load density was positively correlated with body temperature, CRP and CURB-65 scores, and negatively correlated with SpO2 (figure 3; online supplemental file 4).

| Characteristics                | Unadjusted OR (95% CI) | Adjusted OR* (95% CI) |
|--------------------------------|------------------------|-----------------------|
| **Overall**                    | 133 vs 209             | 0.49 (0.29 to 0.83)    | 0.51 (0.27 to 0.94) |
| **Stratified by sex**          |                        |                       |                     |
| Male                           | 74 vs 127              | 0.65 (0.35 to 1.22)    | 0.62 (0.30 to 1.29) |
| Female                         | 59 vs 82               | 0.29 (0.11 to 0.77)    | 0.23 (0.07 to 0.80) |
| **Stratified by age group (years)** |                     |                       |                     |
| <65                            | 48 vs 51               | 0.63 (0.19 to 2.06)    | 0.97 (0.20 to 4.86) |
| ≥65                            | 85 vs 158              | 0.52 (0.29 to 0.94)    | 0.50 (0.25 to 1.01) |
| **Stratified by underlying disorders** |                 |                       |                     |
| Present                        | 75 vs 131              | 0.63 (0.34 to 1.16)    | 0.53 (0.25 to 1.12) |
| Absent                         | 58 vs 78               | 0.27 (0.08 to 0.84)    | 0.24 (0.05 to 1.08) |
| **Stratified by pneumonia type** |                      |                       |                     |
| CAP                            | 116 vs 163             | 0.42 (0.23 to 0.76)    | 0.40 (0.20 to 0.82) |
| HCAP                           | 17 vs 46               | 1.26 (0.41 to 3.87)    | 1.44 (0.26 to 8.04) |
| **Stratified by chest radiograph findings** |        |                       |                     |
| Lobar pneumonia                | 102 vs 153             | 0.43 (0.23 to 0.79)    | 0.37 (0.17 to 0.79) |
| Bronchopneumonia               | 31 vs 56               | 0.73 (0.28 to 1.96)    | 1.01 (0.29 to 3.52) |

*ORs were adjusted for patient’s sex, age, age group, vaccination status, present smoking, underlying diseases, prehospital antibiotic use, study site, study period, pneumonia type, hypoxaemia and severity score (CURB-65).
†Wald test was used for the test of interaction.

CAP, community-acquired pneumonia; CURB-65, Confusion, blood Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and older; HCAP, healthcare-acquired pneumonia.

---

Table 3

Comparing associated characteristics of multiple-serotype pneumococcal pneumonia with single-serotype pneumococcal pneumonia

Table 4

Stratified analysis of the association between 23-valent pneumococcal polysaccharide vaccine (PPSV23) and multiple-serotype pneumococcal pneumonia.
Figure 3 Distribution of pneumococcal serotypes. Bar diagram showing the distribution of pneumococcal serotype/serogroups in single-serotype pneumococcal pneumonia (number of serotypes=276) and multiple-serotype pneumococcal pneumonia (number of serotypes=481). Blue bar represents serotype distribution in single-serotype pneumonia, whereas orange, green and purple bars represent serotype distributions of first, second and third dominant serotypes in multiple-serotype pneumonia. PPSV23, 23-valent pneumococcal polysaccharide vaccine.

DISCUSSION
This multicentre study of adult pneumonia showed that multiple serotypes were prevalent in pneumococcal pneumonia. To best of our knowledge, this is the first study that describes the demographic and clinical characteristics of multiple-serotype pneumococcal pneumonia in adults. Compared with single-serotype pneumonia, the risk of multiple-serotype pneumonia was lower among patients who had taken PPSV23 vaccine in last 5 years, and the risk was much lower in female sex. Serotype distributions in single-serotype and multiple-serotype pneumonias were different, and the proportion of non-PCV7 PPSV23 serotypes was significantly higher in multiple-serotype pneumonia than single-serotype pneumonia.

Multiple-serotype pneumonia constituted 42% of pneumococcal pneumonia. This high prevalence was in concordance with a high prevalence (50%) of multiple serotypes detected as carriage in healthy adults in Japan. Pneumococcal pathogenesis starts with nasopharyngeal colonisation; two or more than two serotypes can colonise at the same time, and studies in children have shown that the multiple-serotype colonisation is associated with pneumonia. Multiple-serotype colonisation, which we assume the precursor of multiple-serotype pneumonia, has implications for vaccine serotype replacement, pneumonia diagnosis and antimicrobial resistance. Therefore, it is important to explore the epidemiological and clinical characteristics of multiple-serotype pneumonia.

Most studies of pneumococcal invasive diseases show single serotypes. Conventionally, serotypes are determined by Quellung reaction on one or two colonies picked up from the culture plate. Molecular methods, such as real-time PCR show higher sensitivity to detect multiple serotypes than WHO-recommended culture method. When multiple serotypes are present in the culture plate, dominant serotype is generally picked up by the conventional method. In this study, 14 patients had serotyping results of blood culture isolates, 6 of them had multiple serotypes by PCR and the serotypes identified by the conventional method were all of the dominant ones identified by PCR. Our data also show that there is about 100 folds (2 log10) difference in bacterial loads between dominant and subdominant serotypes. Therefore, in sputum culture, to detect 2 serotypes, we probably need to serotype 100 colonies. However, this ratio of bacterial loads in invasive disease is unknown. Our colonisation study in healthy elderly in Japan shows that the median bacterial load is 3.98 log10/mL in saliva or nasopharyngeal samples (data not published), which is 100 times lower than that of second dominant serotype (6 log10/mL) in multiple-serotype pneumonia. Due to such a high bacterial load of second dominant serotypes, we think at least second dominant serotypes may have a pathological role in non-invasive pneumonia. However, it may be possible that the most dominant serotypes are the ones that often invade into the circulation.

Receiving PPSV23 vaccine within 5 years was associated with a lower risk of multiple-serotype pneumonia. The risk was much lower in female sex, patients with CAP and patients with lobar pneumonia (although not significantly due a small sample size). Studies have shown that the effectiveness of PPSV23 is higher among female patients than male patients. The reasons behind higher immune response among female patients are not fully known; however, humoral responses as well as type III hypersensitivity reactions are found to be stronger in female patients. Our observation of lower risk of multiple-serotype pneumonia in comparison with single-serotype in PPSV23-vaccinated female patients is in line with the implications of the previous studies; however, the mechanisms of protection by PPSV23 vaccine in this pneumonia group, needs to be elucidated. We observed the risk of multiple-serotype pneumonia was lower in PPSV23-vaccinated patients than not-vaccinated patients, and the proportion of multiple-serotype pneumonia was significantly higher in CAP than HCAP (45.5% vs 29.1%, p=0.004); that may lead to a much lower risk of CAP than HCAP among PPSV23-vaccinated patients. We did not find any protection of the vaccine against multiple-serotype pneumonia after 5 years of the vaccination; however, we think a larger study is needed. In this study, the sample size of the vaccinated for >5 years was small, six in multiple-serotype and seven in single-serotype pneumonias (data not shown).

We found that the proportion of non-PCV7 PPSV23 or non-PCV13 PPSV23 serotypes was significantly higher in multiple-serotype pneumonia than single-serotype pneumonia. Serotypes 5, 9N/9L, 10A, 12/44/46, 17F and 35F were found to be
Table 5  Overall serotype distribution in multiple-serotype pneumococcal pneumonia and single-serotype pneumococcal pneumonia

| Serotypes               | Number of serotypes in multiple-serotype pneumococcal pneumonia | Number of serotypes in single-serotype pneumococcal pneumonia | OR (95% CI) | P value† |
|-------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|-------------|---------|
| PCV7 serotypes          |                                                                 |                                                                |             |         |
| Serotype 4, n (%)       | 25 (5.2)                                                        | 7 (2.5)                                                        | 2.1 (0.87 to 5.82) | 0.079  |
| Serotype 6A/6B, n (%)   | 20 (4.2)                                                        | 23 (8.3)                                                       | 0.48 (0.24 to 0.93) | 0.016  |
| Serotype 9V/9A, n (%)   | 2 (0.4)                                                         | 3 (1.1)                                                        | 0.38 (0.03 to 3.34) | 0.360  |
| Serotype 14, n (%)      | 13 (2.7)                                                        | 7 (2.5)                                                        | 1.07 (0.39 to 3.20) | 0.890  |
| Serotype 18, n (%)      | 14 (2.9)                                                        | 2 (0.7)                                                        | 4.10 (0.93 to 37.4) | 0.063  |
| Serotype 19F, n (%)     | 18 (3.7)                                                        | 18 (6.5)                                                       | 0.56 (0.27 to 1.16) | 0.083  |
| Serotype 23F, n (%)     | 3 (0.6)                                                         | 9 (3.3)                                                        | 0.19 (0.03 to 0.76) | 0.011  |
| Additional serotypes in PCV13 |                                                              |                                                                |             |         |
| Serotype 1, n (%)       | 6 (1.2)                                                         | 0 (0.0)                                                        | NA          |         |
| Serotype 5, n (%)       | 25 (5.2)                                                        | 2 (0.7)                                                        | 7.51 (1.85 to 65.8) | 0.001  |
| Serotype 7F/7A, n (%)   | 4 (0.8)                                                         | 0 (0.0)                                                        | NA          |         |
| Serotype 3, n (%)       | 53 (11.0)                                                       | 44 (15.9)                                                      | 0.65 (0.42 to 1.03) | 0.051  |
| Serotype 19A, n (%)     | 29 (6.0)                                                        | 12 (4.3)                                                       | 1.41 (0.68 to 3.09) | 0.325  |
| Non-PCV13 PPSV23 serotypes |                                                              |                                                                |             |         |
| Serotype 2, n (%)       | 5 (1.0)                                                         | 0 (0.0)                                                        | NA          |         |
| Serotype 8, n (%)       | 2 (0.4)                                                         | 0 (0.0)                                                        | NA          |         |
| Serotype 9N/9L, n (%)   | 22 (4.6)                                                        | 1 (0.4)                                                        | 13.2 (2.1 to 545) | 0.001  |
| Serotype 10A, n (%)     | 82 (17.0)                                                       | 22 (8.0)                                                       | 2.37 (1.42 to 4.09) | 0.001  |
| Serotype 11, n (%)      | 15 (3.1)                                                        | 21 (7.6)                                                       | 0.39 (0.18 to 0.81) | 0.005  |
| Serotype 12/44/46, n (%)| 16 (3.3)                                                        | 1 (0.4)                                                        | 9.46 (1.45 to 398) | 0.008  |
| Serotype 15B/15C, n (%) | 15 (3.1)                                                        | 5 (1.8)                                                        | 1.74 (0.59 to 6.20) | 0.350  |
| Serotype 17F, n (%)     | 23 (4.8)                                                        | 1 (0.4)                                                        | 13.8 (2.21 to 570) | 0.001  |
| Serotype 20, n (%)      | 2 (0.4)                                                         | 1 (0.4)                                                        | 1.15 (0.06 to 68.0) | 1.000  |
| Serotype 22F/22A, n (%) | 17 (3.5)                                                        | 13 (4.7)                                                       | 0.74 (0.33 to 1.69) | 0.425  |
| Serotype 33F/33A/37, n (%)| 8 (1.7)                                                        | 5 (1.8)                                                        | 0.92 (0.26 to 3.60) | 1.000  |
| Other serotypes        |                                                                |                                                                |             |         |
| Serotype 6C/6D, n (%)   | 14 (2.9)                                                        | 18 (6.5)                                                       | 0.43 (0.19 to 0.93) | 0.018  |
| Serotype 23A, n (%)     | 11 (2.3)                                                        | 5 (1.8)                                                        | 1.27 (0.40 to 4.71) | 0.800  |
| Serotype 34, n (%)      | 8 (1.7)                                                         | 4 (1.4)                                                        | 1.15 (0.30 to 5.27) | 1.000  |
| Serotype 35F, n (%)     | 12 (2.5)                                                        | 1 (0.4)                                                        | 7.04 (1.03 to 301) | 0.039  |
| Serotype 35B, n (%)     | 17 (3.5)                                                        | 18 (6.5)                                                       | 0.53 (0.25 to 1.10) | 0.060  |

*NT serotypes were 33 (12.0%). These samples were ly4 PCR positive but could not be serotyped by our present system. It may be possible that some of these samples may contain multiple serotypes beyond the 50 serotypes that the nanofluidic PCR system could detect. As the median bacterial load of NT was almost 1 log10/mL lower than that of multiple serotypes, we considered most of NT were essentially single serotypes.
†Fisher’s exact rest was performed when the number of serotypes was ≤5 in any of the cells.

NT, non-typeable; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

associated with multiple-serotype pneumonia, whereas serotypes 6A/6B, 23F, 11 and 6C/6D were associated with single-serotype pneumonia. Among these serotypes, from our previous study of serotype-specific vaccine effectiveness of PPSV23, we found the point estimates of the vaccine effectiveness for serotype 10A was 30.5%, and for serotype 6A/6B, it was −35.9%. Because of the small sample size, serotype-specific vaccine effectiveness could not be calculated for all these serotypes in that study; from our observation of the association of serotype 10A with multiple-serotype pneumonia and serotype 6A/6B with single-serotype pneumonia in this study, it is plausible that the vaccine effectiveness of the PPSV23 could be higher among the serotypes prevalent in multiple-serotype pneumonia, especially non-PCV7 PPSV23 or non-PCV13 PPSV23 serotypes than those prevalent in single-serotype pneumonia.

Our data show the proportions of serotype coverage by PCV13 and PPSV23 were 46% and 71.4%, respectively in single-serotype pneumonia; other studies show the proportion of PCV13 serotypes from 40.2% to 46.0% and PPSV23 serotypes from 63.1% to 66.0% among adults in Japan in the study period from 2013 to 2016. We found a higher proportion of PPSV23 serotypes in multiple-serotype pneumonia (87.1%) than single-serotype pneumonia (71.4%) (p=0.001); this was mostly because of a significantly higher proportion of non-PCV13 PPSV23 serotypes in multiple-serotype pneumonia as discussed above.

Routine serotype surveillance is important as non-PCV13 serotypes have emerged to cause pneumococcal diseases after introduction of the pneumococcal conjugate vaccines, and these replacement diseases most commonly occur in elderly. Comparing serotype distribution before and after introduction of PCV13 in Japan, a study has found that the proportions of the non-PCV13 serotypes, such as 11A, 35B and 33F have increased significantly, along with vaccine serotype 3 after introduction of PCV13 in Japan. In our study, non-vaccine serotypes (non-PCV13 serotypes) 9N/9L, 10A, 12/44/46, 17F and 35F were
Respiratory infection

associated with multiple-serotype pneumonia, and serotype 11 and 6C/6D were associated with single-serotype pneumonia. As the proportion of non-vaccine serotypes (non-PCV13 PPSV23) was found to be significantly higher in multiple-serotype pneumonia than single-serotype pneumonia, we believe that the emergence of non-PCV13 vaccine serotypes would be more common in multiple-serotype pneumonia than single-serotype pneumonia after introduction of PCV13.

Very few colonisation studies have been conducted in adults and elderly in Japan. A study conducted in 2011 shows that serotype 3 (19.0%), 19F (14.3%), 11A (12.7%), 23F (9.5%), 6B (9.5%) and 15B (7.9%) were common. Our study showed

Figure 4  Bacterial density in single-serotype pneumococcal pneumonia and multiple-serotype pneumococcal pneumonia. Box and whisker plot showing the distribution of bacterial density of serotypes in single-serotype pneumococcal pneumonia and multiple-serotype pneumococcal pneumonia in order of dominance. The total number of serotypes identified was 242 in single-serotype pneumonia and 481 in multiple-serotype pneumonia.

Figure 5  Scatter plot showing the relationship between pneumococcal bacterial density and C-reactive protein in single-serotype pneumococcal pneumonia and multiple-serotype pneumococcal pneumonia. Solid lines represent the linear regression fit across the patients. Spearman’s rank correlation coefficients were 0.205 (p=0.001) and 0.184 (p=0.009) for single-serotype pneumococcal pneumonia and multiple-serotype pneumococcal pneumonia, respectively.
that serotype 3 was dominant both in single-serotype pneumonia (15.9%) as well as multiple-serotype pneumonia (11.0%), 19F was fifth common (6.5%), 11 was fourth common (7.6%) and 6B was second common (8.3%) in single-serotype pneumonia. ‘Highly invasive serotypes’, such as serotype 1 (1.2%), 5 (5.2%), 7F (0.8%) and 8 (0.4%) were detected in our cohort of multiple-serotype pneumonia, but not in the colonisation study. The other study was conducted in 2018, and it showed that serotype 10A, 12 and 35F were common (sample size, n=22). We found bacterial density of one serotype was dominant to that of other serotypes in multiple-serotype pneumonia. This dominance of one serotype is similar to the findings when more than one serotypes are present in nasopharyngeal colonisation in healthy babies and children with acute respiratory tract infections. These similarities in density of serotypes in colonisation and in pneumonia may indicate that the multiple-serotype colonisation could be the precursor of multiple-serotype infections. This is also supported by the high prevalence of carriage of multiple serotypes in saliva of healthy adults.

Our study has limitations. We defined pneumococcal pneumonia when PCR was positive with a bacterial density ≥10^7/mL; although it is a robust technique and is being used increasingly for the diagnosis, we might have included some cases of carriage in the sputum, as the PCR had sensitivity of 85.4% and specificity of 94.6% at that bacterial load cut-off. Another limitation is that the nanofluidic PCR system can only detect 50 serotypes; therefore, the characteristics of non-typeable serotypes could not be determined. Clinical and epidemiological characteristics of individual serotypes could not be explored because of low numbers of the serotypes. Similarly, we could not follow-up the patients to know some outcomes, such as 30-day mortality; therefore, their association with multiple-serotype pneumonia could not be examined.

CONCLUSION
We found a high prevalence of multiple serotypes of pneumococci in adult patients with pneumonia. The risk of multiple-serotype pneumonia was lower among those who were PPSV23 vaccinated. We observed a significantly higher proportion of non-PCV13 PPSV23 serotypes in multiple-serotype pneumonia than single-serotype pneumonia that may have implication for differential vaccine effectiveness of PPSV23 between these two groups of patients.

Author affiliations
1Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
2Department of Global Health, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
3Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan
4Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
5Department of Internal Medicine, Kameda Medical Center, Chiba, Japan
6Department of Internal Medicine, Juzenkai Hospital, Nagasaki, Japan
7Department of Pulmonology, Kameda Medical Center, Chiba, Japan
8Department of Pulmonology, Kameda Medical Center, Chiba, Japan
9Life Science Institute, Saga-Ken Medical Centre Koseikan, Saga, Japan

Acknowledgements
We would like to thank Kyoko Uchibori, Rina Shiramizu and Yumi Araki for their technical help.

Collaborators
Adult Pneumonia Study Group-Japan (APSG-J): collaborators: Masahiko Abe (Ebetsu City Hospital, Hokkaido, Japan), Masayuki Chikamori (Chikamori Hospital, Kochi, Japan), Akitsu Furumoto (Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan), Naohisa Hamashige (Chikamori Hospital, Naoto Hosokawa (Kameda Medical Centre, Chiba, Japan), Hiroki Kato (Institute of Tropical Medicine, Nagasaki University and Juzenkai Hospital, Nagasaki, Japan), Satoshi Kikuchi, (Institute of Tropical Medicine, Nagasaki University), Norihiro Kaneko (Kameda Medical Centre), Shungo Katoh (Ebetsu City Hospital and Institute of Tropical Medicine, Nagasaki University), Naoko Katsumura (Kameda Medical Centre), Emi Kitashoji (Institute of Tropical Medicine, Nagasaki University), Kei Matsuki (Juzenkai Hospital), Hiroshi Nakaoka (Chikamori Hospital and Institute of Tropical Medicine, Nagasaki University), Kei Nakashima (Kameda Medical Centre), Yoshiohito Otsuka (Kameda Medical Centre), Eiichiro Sando (Kameda Medical Centre), Kaori Shibui (Kameda Medical Centre), Takaharu Shimazaki (Institute of Tropical Medicine, Nagasaki University), Daisuke Suzuki (Kameda Medical Centre), Masahiro Takaki (Institute of Tropical Medicine, Nagasaki University), Kenzo Tanaka (Kameda Medical Centre), Kentarou Tochitani (Kameda Medical Centre), Yoshiho Tsunashita (Juzenkai Hospital), Takao Wakabayashi (Ebetsu City Hospital), Kiwao Watanabe (Institute of Tropical Medicine, Nagasaki University), Lay-Min Yoshida (Institute of Tropical Medicine, Nagasaki University).

Contributors
BGD, MS, KA and KM (guarantor) proposed the study. MS, TI, MYae, NA, MI, Sh, MA and KM trained clinicians and staffs on study protocols and supervised the study in the hospitals. BGD, TI and MYas did serotyping in Nagasaki. BGD and MS did the analysis. BGD, MS, KA and KM clarify the findings. BGD and MS drafted the first report. KM is the guarantor of the paper. All authors contributed to the final manuscript.

Funding
This study was supported by Pfizer (grant numbers W1182481 and WS1874254) and Nagasaki University.

Disclaimer
The funders did not have any role in study design, data collection and analysis, manuscript preparation and decision to publish.

Competing interests
KM declares speaker fees from Eli Lilly, Takeda and Asahi Kasel Pharma. KA declares speaker fees from Pfizer and Kyorin Pharma. No other authors declare any competing interests.

Patient consent for publication
Not applicable.

Ethics approval
The study was approved by the review boards of Institute of Tropical Medicine (Nagasaki University) and the hospitals (reference number or ID: 11063070). We took a written informed consent from all conscious patients. Because the study was observational and there was no invasive intervention or any deviation from the current medical treatment, the necessity of taking an informed written consent was waived in few cases of unconscious patients by all the institutional review boards.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request. Data related to this study are available on reasonable request to the corresponding author.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Bhim Gopal Dhoubhadel http://orcid.org/0000-0001-5279-2044
Moti Suzuki http://orcid.org/0000-0002-9401-466X
Kosuke Morimoto http://orcid.org/0000-0003-2912-9919

REFERENCES
1 Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018;18:441–51.
2 Hanquet G, Kirova P, Valentinier-Barranti R, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax 2019;74:473–82.
3 Demczuk WNB, Martin I, Desai S, et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016. Vaccine 2018;36:4701–7.
Respiratory infection

4 Menzies RJ, Jardine A, McIntyre PB. Pneumonia in elderly Australians: reduction in presumptive pneumococcal hospitalizations but no change in all-cause pneumonia hospitalizations following 7-valent pneumococcal conjugate vaccination. *Clin Infect Dis* 2015;61:927–33.

5 Sandol E, Suzuki M, Furumoto A, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: the Japan pneumococcal vaccine effectiveness study (J-PAVE). *Vaccine* 2019;37:2687–93.

6 Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. *J Infect Dis* 2013;208:1813–20.

7 Miyishi EN, Oliveira MLS, Carvalho E, et al. Serotype-independent pneumococcal vaccines. *Cell Mol Life Sci* 2013;70:3203–26.

8 Albracht WC, Madhi SA, Adrian PV, et al. Genomic load from sputum samples and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-infected adults. *J Clin Microbiol* 2014;52:4224–9.

9 Saikko T, Palku AA, Pascal T, et al. Quantitative PCR on Sputum and Nasopharyngeal Swab Samples for Detection of Pneumococcal Pneumonia among the Elderly. *J Clin Microbiol* 2018;56. doi:10.1128/JCM.01231-17. [Epub ahead of print: 26 Apr 2017].

10 Yang S, Lin S, Kihal A, et al. Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. *J Clin Microbiol* 2005;43:3221–6.

11 Johansson N, Kalm M, Giske CG, et al. Quantitative detection of Streptococcus pneumoniae from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia. *Diagn Microbiol Infect Dis* 2008;60:255–61.

12 Satria K, Herrmann B, Abdeldataim G, et al. Comparison of sputum and nasopharyngeal aspirate samples and of the PCR gene targets lta and Spn9802 for quantitative PCR for rapid detection of pneumococcal pneumonia. *J Clin Microbiol* 2014;52:83–9.

13 Ndlangisa K, du Plessis M, Alam M, et al. Invasive disease caused simultaneously by two dual serotypes of Streptococcus pneumoniae. *J Clin Microbiol* 2018;56. doi:10.1128/JCM.01149-17. [Epub ahead of print: 26 Dec 2017].

14 Chaves F, Campello C, Sanz F, et al. Meningitis due to mixed infection with penicillin-resistant and penicillin-susceptible strains of Streptococcus pneumoniae. *J Clin Microbiol* 2003;41:512–3.

15 de Andrade ALS, Pimenta FC, Laval CAB, et al. Invasive pneumococcal infection in a infant healthy caused by two different serotypes. *J Clin Microbiol* 2004;42:2345–6.

16 Shak JR, Vidal JE, Klugman KP. Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. *Trends Microbiol* 2013;21:129–35.

17 Marks LR, Reddinger RM, Hakansson AP. High levels of genetic recombination during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. *mbio* 2012;3. doi:10.1128/mBio.00200-12. [Epub ahead of print: 25 09 2012].

18 Kamminga AW, Hinds J, Bar-Zewi N, et al. High multiple carriage and emergence of Streptococcus pneumoniae vaccine serotype variants in Malaysian children. *BMJ Infect Dis* 2015;15:234.

19 Kakuki S, Suzuki M, Dhubhadel BG, et al. Accuracy of high-throughput nanoparticle PCR-based pneumococcal serotyping and quantification assays using sputum samples for diagnosing vaccine serotype pneumococcal pneumonia: analyses by composite diagnostic standards and Bayesian latent class models. *J Clin Microbiol* 2018;56. doi:10.1128/JCM.01874-17. [Epub ahead of print: 25 04 2018].

20 Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. *PLoS One* 2015;10:e0122247.

21 Suzuki M, Dhubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. *Lancet Infect Dis* 2017;17:313–21.

22 Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases Society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44 Suppl 2:S272–77.

23 American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388–416.

24 Dhubhadel BG, Yasunami M, Yoshida L-M, et al. A novel high-throughput method for molecular serotyping and serotype-specific quantification of Streptococcus pneumoniae using a nanofluidic real-time PCR system. *J Med Microbiol* 2014;63:528–39.

25 Yoshida LM, Suzuki M, Yamamoto T, et al. Viral pathogens associated with acute respiratory infections in central Vietnamese children. *Pediatr Infect Dis J* 2010;29:75–7.

26 Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. *Thorax* 2012;67:540–5.

27 Chiba N, Morozumi M, Shouji M, et al. Changes in capsule and drug resistance of Pneumococcus after introduction of PCV7, Japan, 2010-2013. *Emerg Infect Dis* 2014;20:1132–9.

28 Naito T, Matsuda N, Tanei M, et al. Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the great East Japan earthquake. *J Infect Chemother* 2014;20:450–5.

29 Wiemken TL, Carrio RM, Klein SI, et al. The effectiveness of the polysaccharide pneumococcal pneumonia community-acquired pneumonia in the elderly differs between the sexes: results from the community-acquired pneumonia organization (CAPO) international cohort study. *Vaccine* 2014;32:2198–203.

30 Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the region of Madrid, Spain, 2008-2011. *Euro Surveill* 2014;19:20922.

31 Yasuda I, Suzuki M, Dhubhadel BG, et al. The low carriage prevalence of Streptococcus community-dwelling older people: a cross-sectional study. *J Infect Dis* 2020;38:3752–8.

32 Bogaert D, De Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. *Lancet Infect Dis* 2004;4:144–54.

33 Dhubhadel BG, Yasunami M, Nguyen HAT, et al. Bacterial load of pneumococcal serotypes correlates with their prevalence and multiple serotypes is associated with acute respiratory infections among children less than 5 years of age. *PloS One* 2014;9:e110777.

34 Shah JR, Vidal JE, Klugman KP. Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. *Trends Microbiol* 2013;21:129–35.

35 Azzari C, Resti M. Reduction of carriage and transmission of Streptococcus pneumoniae: the beneficial "side effect" of pneumococcal conjugate vaccine. *Clin Infect Dis* 2008;47:997–9.

36 Voysey M, Barker CIS, Snape MD, et al. Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. *Vaccine* 2016;34:1657–64.

37 Cook IE. Sex differences in injection site reactions with human vaccines. *Hum Vaccin 2009;5:441–9.

38 Klein SL, Jedlicka A, Pekosz A, The Xs and Y of immune responses to viral vaccines. *Lancet Infect Dis* 2010;10:338–49.

39 Fukusumi M, Chang B, Tanabe Y, et al. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution. *Emerg Infect Dis* 2017;23:172.

40 Miyazaki H, Shibuya R, Midorikawa N, et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Japan after introduction of the routine immunization program. *J Infect Chemother* 2017;23:234–40.

41 van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. *Lancet* 2009;374:1543–56.

42 Furuya T, Yamagishi Y, Okade H, et al. Impact of the pneumococcal conjugate vaccine on seroprevalence of adult non-invasive Streptococcus pneumoniae isolates in Tokai region, Japan, 2008-2016. *J Infect Chemother* 2017;23:394–9.

43 Kagawa-Yasuda M, Ushiribana N, Ghosh S, et al. Serotype distribution and susceptibility to penicillin and erythromycin among noninvasive or colonization isolates of Streptococcus pneumoniae in northern Japan: a cross-sectional study in the pre-PCV7 routine immunization period. *Microb Drug Resist* 2014;20:456–65.

44 Olwagen CP, Adrian PV, Madhi SA. Comparison of traditional culture and molecular qPCR for detection of simultaneous carriage of multiple pneumococcal serotypes in African children. *Sci Rep* 2017;7:4628.
### Online supplementary table 1. Characteristics of patients with pneumonia by sputum available for PCR

| Characteristics                      | Sputum available, n=2605 | Sputum not-available, n=865 | P value   |
|--------------------------------------|---------------------------|-----------------------------|-----------|
| Age, median (IQR), years             | 78 (66-85)                | 74 (61-83)                  | <0.001    |
| Age group ≥65 years, n (%)           | 2029 (77.9)               | 592 (68.4)                  | 0.001     |
| Male sex, n (%)                      | 1581 (60.7)               | 485 (56.1)                  | 0.016     |
| Study site, n (%)                    |                           |                             | 0.001     |
| Ebetsu City Hospital                 | 326 (12.5)                | 98 (11.3)                   |           |
| Kameda Medical Centre                | 1369 (52.5)               | 686 (79.3)                  |           |
| Chikamori Hospital                   | 598 (23.0)                | 10 (1.2)                    |           |
| Jyuzenkai Hospital                   | 312 (12.0)                | 71 (8.2)                    |           |
| Fever (Temperature ≥38.0°C), n=3369 (%) | 780 (30.5)               | 229 (28.3)                  | 0.242     |
| Hypoxemia (SpO2 <90%), n=3340 (%)    | 323 (12.8)                | 67 (8.3)                    | 0.001     |
| Leukocytosis (>11000 WBC/mm³), n=3390 (%) | 993 (38.7)               | 296 (35.9)                  | 0.145     |
| Raised c-reactive protein (>10      | 869 (34.1)                | 227 (27.8)                  | 0.001     |
mg/dL, n=3368 (%)

|                      | 1743 (66.9) | 603 (69.7) | 0.127 |
|----------------------|-------------|------------|-------|
| Chest x-ray (Lobar consolidation), n=3470 (%) | 1743 (66.9) | 603 (69.7) | 0.127 |
| Received PPSV23 in last 5 years, n=2033 (%) | 566 (31.1) | 51 (23.9) | 0.032 |
| Current smoker, n=1520 (%) | 242 (17.5) | 30 (22.4) | 0.155 |
| COPD, n=3470 (%) | 564 (21.7) | 172 (19.9) | 0.271 |
| Asthma, n=3470 (%) | 265 (10.2) | 66 (7.6) | 0.027 |
| Risk of aspiration, n=2816 (%) | 1357 (53.4) | 163 (59.5) | 0.054 |
| Diabetes mellitus, n=3470 (%) | 537 (20.6) | 167 (19.3) | 0.407 |
| CURB-65 score ≥3, n=3359 (%) | 806 (31.6) | 244 (30.2) | 0.455 |

SpO2, saturation of peripheral oxygen; WBC, white blood cells; PPSV23, 23-valent pneumococcal polysaccharide vaccine; COPD, chronic obstructive pulmonary disease; RSV, respiratory syncytial virus.

CURB-65 includes scores for confusion, blood urea nitrogen >20 mg/dL, respiratory rate ≥30/minute, blood pressure <90/60 mm Hg and age ≥65 years.
### Online supplementary table 2. Characteristics of PPSV23 vaccinated and not-vaccinated patients

| Characteristics                | PPSV23 Vaccinated | PPSV23 Not-vaccinated | P value |
|-------------------------------|-------------------|-----------------------|---------|
| Age, median (IQR)             | 80 (74-86)        | 75 (61-84)            | <0.001  |
| Age group ≥65 years, n (%)    | 569 (92.2)        | 967 (68.3)            | <0.001  |
| Male sex, n (%)               | 393 (63.7)        | 795 (56.1)            | 0.002   |
| Current smoker, n=1106 (%)    | 25 (6.8)          | 182 (24.7)            | <0.001  |
| Underlying diseases, n (%)    | 450 (72.9)        | 775 (54.7)            | <0.001  |
| Study site, n (%)             |                   |                       |         |
| Ebetsu City Hospital          | 47 (7.6)          | 269 (19.0)            | <0.001  |
| Kameda Medical Centre         | 503 (81.5)        | 635 (44.8)            |         |
| Chikamori Hospital            | 37 (6.0)          | 223 (15.8)            |         |
| Jyuzenkai Hospital            | 30 (4.9)          | 289 (20.4)            |         |
**Online supplementary table 3. Characteristics of patients with pneumonia by PPSV23 vaccination status**

| Characteristics                  | PPSV23 vaccine status known n=2033 | PPSV23 vaccine status unknown n=1437 | P value |
|----------------------------------|-----------------------------------|-------------------------------------|---------|
| **Age, median (IQR)**            | 77 (65-85)                        | 78 (65-85)                          | 0.966   |
| **Age group ≥65 years, n (%)**   | 1536 (75.6)                       | 1085 (75.5)                         | 0.974   |
| **Male sex, n (%)**              | 1188 (58.4)                       | 878 (61.1)                          | 0.115   |
| **Study hospital, n (%)**        |                                   |                                     | 0.001   |
| Ebetsu City Hospital             | 316 (15.5)                        | 108 (7.5)                           |         |
| Kameda Medical Centre            | 1138 (56.0)                       | 917 (63.8)                          |         |
| Chikamori Hospital               | 260 (12.8)                        | 348 (24.2)                          |         |
| Jyuzenkai Hospital               | 319 (15.7)                        | 64 (4.5)                            |         |
| **Fever (Temperature ≥38.0°C), n=3369 (%)** |                       |                                     | 0.958   |
| Hypoxemia (SpO2 <90%), n=3340 (%) | 224 (11.3)                        | 166 (12.2)                          | 0.422   |
| Leukocytosis (>11000 WBC/mm³), n=3390 (%) | 754 (37.8)                        | 535 (38.4)                          | 0.742   |
| C-reactive protein (>10 mg/dL),  | 678 (34.2)                        | 418 (30.2)                          | 0.016   |
| Condition                                      | n=3368 (%) | Lobar pneumonia, n=3470 (%) | 1416 (69.6) | 930 (64.7) | 0.002 |
|-----------------------------------------------|------------|-----------------------------|--------------|------------|-------|
| CAP                                           |            | 1378 (67.8)                | 895 (62.3)   | 0.001     |       |
| Current smoker, n=1520 (%)                    |            | 207 (18.7)                 | 65 (15.7)    | 0.172     |       |
| Underlying diseases, n=3470 (%)               |            | 1225 (60.3)                | 875 (60.9)   | 0.706     |       |
| CURB-65 score ≥3, n=3359 (%)                  |            | 574 (29.0)                 | 476 (34.6)   | 0.001     |       |
| Pneumococcal pneumonia, n=2605 (%)            |            | 342 (18.8)                 | 134 (17.1)   | 0.297     |       |

SpO2, saturation of peripheral oxygen; CAP, community acquired pneumonia.

CURB-65 includes scores for confusion, blood urea nitrogen >20 mg/dL, respiratory rate ≥30/minute, blood pressure <90/60 mm Hg and age ≥65 years.
Supplementary table 4. Correlations of pneumococcal load density (log10/mL) in sputum with clinical characteristics in single-serotype pneumococcal pneumonia and multiple-serotype pneumococcal pneumonia

| Characteristics | Single-serotype pneumococcal pneumonia | Multiple-serotype pneumococcal pneumonia |
|-----------------|----------------------------------------|-----------------------------------------|
|                 | Spearman’s rho | P value | Spearman’s rho | P value |
| Body temperature (°C) | 0.085 | 0.157 | 0.161 | 0.023 |
| WBC (/mm³)      | 0.027 | 0.652 | -0.007 | 0.922 |
| CRP (mg/L)      | 0.205 | 0.001 | 0.184 | 0.009 |
| SpO₂ (%)        | -0.208 | 0.001 | -0.136 | 0.059 |
| CURB-65         | 0.180 | 0.002 | 0.196 | 0.005 |

WBC, white blood cells; CRP, C-reactive protein; SpO₂, saturation of peripheral oxygen. CURB-65 includes scores for confusion, blood urea nitrogen >20 mg/dL, respiratory rate ≥30/minute, blood pressure <90/60 mm Hg and age ≥65 years.
Supplementary figure 1. Venn diagram showing the results of positive results from PCR (bacterial load $\geq 10000$/mL in sputum) (n=476), positive urine antigen test (n=290) and positive blood culture (n=21). PCR and urine antigen test were positive in 169; PCR and blood culture were positive in 19; urine antigen test and blood culture were positive in 16; and all were positive in 15 patients.
Online supplementary file 6

Covariates

Demographic and clinical information, including age, sex, smoking status, pre-hospital antibiotic treatment, body temperature, respiration rate, peripheral oxygen level (SpO₂), findings of laboratory and radiological investigations, past medical histories, co-morbidity conditions and PPSV23 vaccination status were collected from medical records of the patients. Patients or their guardians confirmed the PPSV23 vaccination status. Age was categorised into <65 years and ≥65 years groups. Information about pneumococcal serotypes and viruses were obtained after the laboratory investigation in the Department of Clinical Medicine, Institute of Tropical Medicine in Nagasaki. The primary outcome, multiple-serotype pneumococcal pneumonia was identified when two or more than two serotypes were detected in patients with pneumococcal pneumonia. From previous studies, we considered study site, patient’s age, underlying comorbidity, smoking status, pre-hospital antibiotic treatment and year of hospital visit as potential confounders.²⁹ ³⁰